Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx intends to collaborate with the Japanese MHLW to gain reimbursement prior to commercialization in Japan to ensure broader access to its innovative and clinically proven treatment.
- Pulmonx intends to collaborate with the Japanese MHLW to gain reimbursement prior to commercialization in Japan to ensure broader access to its innovative and clinically proven treatment.
- The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema.
- Physicians use the Pulmonx Chartis Pulmonary Assessment System to help identify potential responders to Zephyr Valve treatment.
- Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a breakthrough device.